Cargando…

Profile of eliglustat tartrate in the management of Gaucher disease [Corrigendum]

Detalles Bibliográficos
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2016
Materias:	Corrigendum
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4939999/ https://www.ncbi.nlm.nih.gov/pubmed/27462161 http://dx.doi.org/10.2147/TCRM.S108027

Ejemplares similares

Eliglustat tartrate for the treatment of adults with type 1 Gaucher disease [Corrigendum]
Publicado: (2015)

Profile of eliglustat tartrate in the management of Gaucher disease
por: Sechi, Annalisa, et al.
Publicado: (2016)

Eliglustat tartrate for the treatment of adults with type 1 Gaucher disease
por: Bennett, Lunawati L, et al.
Publicado: (2015)

Case report of unexpected gastrointestinal involvement in type 1 Gaucher disease: comparison of eliglustat tartrate treatment and enzyme replacement therapy
por: Kim, Yoo-Mi, et al.
Publicado: (2017)

Budget Impact Analysis of Eliglustat for the Treatment of Gaucher Disease Type 1 in the United States
por: Nalysnyk, Luba, et al.
Publicado: (2018)

Stability is maintained in adults with Gaucher disease type 1 switched from velaglucerase alfa to eliglustat or imiglucerase: A sub-analysis of the eliglustat ENCORE trial
por: Pleat, Rebecca, et al.
Publicado: (2016)

A Japanese Patient with Gaucher Disease Treated with the Oral Drug Eliglustat as Substrate Reducing Therapy
por: Komada, Naoto, et al.
Publicado: (2021)

Gaucher Disease Types I and III Responded Well to Substrate Reduction Therapy Using Eliglustat
por: Harai, Nozomi, et al.
Publicado: (2023)

Real‐world effectiveness of eliglustat in treatment‐naïve and switch patients enrolled in the International Collaborative Gaucher Group Gaucher Registry
por: Mistry, Pramod K., et al.
Publicado: (2020)

Skeletal improvement in patients with Gaucher disease type 1: a phase 2 trial of oral eliglustat
por: Kamath, Ravi S., et al.
Publicado: (2014)

The Clinical Efficacy of Imiglucerase versus Eliglustat in Patients with Gaucher's Disease Type 1: A Systematic Review
por: Nabizadeh, Azita, et al.
Publicado: (2018)

Safety and efficacy of eliglustat combined to enzyme replacement therapy for lymphadenopathy in patients with Gaucher disease type 3
por: Lee, Ni-Chung, et al.
Publicado: (2022)

Real-Life Experience with Oral Eliglustat in Patients with Gaucher Disease Previously Treated with Enzyme Replacement Therapy
por: Istaiti, Majdolen, et al.
Publicado: (2022)

Long-term adverse event profile from four completed trials of oral eliglustat in adults with Gaucher disease type 1
por: Peterschmitt, M. Judith, et al.
Publicado: (2019)

The efficacy and safety of add-on 0.1% brimonidine tartrate preserved with sodium chlorite in on-treatment Japanese normal-tension glaucoma patients [Corrigendum]
Publicado: (2015)

The efficacy and safety of add-on 0.1% brimonidine tartrate preserved with sodium chlorite in on-treatment Japanese normal-tension glaucoma patients [Corrigendum]
Publicado: (2015)

Clinical response to eliglustat in treatment-naïve patients with Gaucher disease type 1: Post-hoc comparison to imiglucerase-treated patients enrolled in the International Collaborative Gaucher Group Gaucher Registry
por: Ibrahim, Jennifer, et al.
Publicado: (2016)

Effects of paroxetine, ketoconazole, and rifampin on the metabolism of eliglustat, an oral substrate reduction therapy for Gaucher disease type 1
por: Vu, Lucie, et al.
Publicado: (2020)

Corrigendum to “Retinal thinning in Gaucher disease patients and carriers: Results of a pilot study” [Mol. Genet. Metab. 109 (2013) 221–223]
por: McNeill, Alisdair, et al.
Publicado: (2014)

Pregnancy outcome in women with Gaucher disease type 1 who had unplanned pregnancies during eliglustat clinical trials
por: Lukina, Elena, et al.
Publicado: (2020)

Incremental biomarker and clinical outcomes after switch from enzyme therapy to eliglustat substrate reduction therapy in Gaucher disease
por: Kleytman, Nathaniel, et al.
Publicado: (2021)

P1588: LONG-TERM REAL-WORLD EFFECTIVENESS OF ELIGLUSTAT IN TREATMENT-NAÏVE AND SWITCH PATIENTS ENROLLED IN THE INTERNATIONAL COLLABORATIVE GAUCHER GROUP (ICGG) GAUCHER REGISTRY
por: Mistry, Pramod, et al.
Publicado: (2023)

Outcomes after 8 years of eliglustat therapy for Gaucher disease type 1: Final results from the Phase 2 trial
por: Lukina, Elena, et al.
Publicado: (2018)

Impact on bone microarchitecture and failure load in a patient with type I Gaucher disease who switched from Imiglucerase to Eliglustat
por: Sidhu, Karamjot, et al.
Publicado: (2020)

Outcomes after 18 months of eliglustat therapy in treatment‐naïve adults with Gaucher disease type 1: The phase 3 ENGAGE trial
por: Mistry, Pramod K., et al.
Publicado: (2017)

A Quantitative Systems Pharmacology Model of Gaucher Disease Type 1 Provides Mechanistic Insight Into the Response to Substrate Reduction Therapy With Eliglustat
por: Abrams, Ruth, et al.
Publicado: (2020)

P1541: PRELIMINARY RESULTS OF TWO YEARS FOLLOW-UP OF TYPE 1 GAUCHER DISEASE PATIENTS TREATED WITH ELIGLUSTAT IN TRAZELGA PROJECT.
por: Serrano-Gonzalo, I., et al.
Publicado: (2022)

Suicidal attempt with eliglustat overdose
por: Nadler, Johannes, et al.
Publicado: (2022)

Clinical outcomes after 4.5 years of eliglustat therapy for Gaucher disease type 1: Phase 3 ENGAGE trial final results
por: Mistry, Pramod K., et al.
Publicado: (2021)

Parkinson’s disease managing reversible neurodegeneration [Corrigendum]
Publicado: (2016)

Profile of gantenerumab and its potential in the treatment of Alzheimer’s disease [Corrigendum]
Publicado: (2014)

Pulmonary hemodynamic profile in chronic obstructive pulmonary disease [Corrigendum]
Publicado: (2015)

Corrigendum: Diabetes: how to manage chronic kidney disease
Publicado: (2022)

Corrigendum: ICTV Virus Taxonomy Profile: Ophioviridae
por: García, María Laura, et al.
Publicado: (2018)

Corrigendum: ICTV Virus Taxonomy Profile: Chrysoviridae
por: Ghabrial, Said A., et al.
Publicado: (2018)

Amino acid management of Parkinson’s disease: a case study [Corrigendum]
Publicado: (2016)

Corrigendum to “Evaluation and Management of Skeletal Health in Celiac Disease: Position Statement”
por: Fouda, Mona A., et al.
Publicado: (2017)

Corrigendum to “New Issues in the Management of Osteoporosis”
por: Sirola, Joonas, et al.
Publicado: (2017)

Corrigendum to: Personalized Management of Pheochromocytoma and Paraganglioma
Publicado: (2021)

Corrigendum to ‘Reliability and validity of the multidimensional dyspnea profile in hospitalized Chinese patients with respiratory diseases’
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_koa05cs8sojemb3hv1mec0ok2o